SG176286A1 - Flavonoid hydrogel - Google Patents

Flavonoid hydrogel Download PDF

Info

Publication number
SG176286A1
SG176286A1 SG2011088283A SG2011088283A SG176286A1 SG 176286 A1 SG176286 A1 SG 176286A1 SG 2011088283 A SG2011088283 A SG 2011088283A SG 2011088283 A SG2011088283 A SG 2011088283A SG 176286 A1 SG176286 A1 SG 176286A1
Authority
SG
Singapore
Prior art keywords
hydrogel
flavonoid
cell
conjugates
cells
Prior art date
Application number
SG2011088283A
Other languages
English (en)
Inventor
Motoichi Kurisawa
Fan Lee
Joo Eun Chung
Pui Yik Peggy Chan
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG176286A1 publication Critical patent/SG176286A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2397/00—Characterised by the use of lignin-containing materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
SG2011088283A 2009-05-29 2010-05-17 Flavonoid hydrogel SG176286A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21333109P 2009-05-29 2009-05-29
PCT/SG2010/000185 WO2010138082A1 (en) 2009-05-29 2010-05-17 Flavonoid hydrogel

Publications (1)

Publication Number Publication Date
SG176286A1 true SG176286A1 (en) 2012-01-30

Family

ID=43222961

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011088283A SG176286A1 (en) 2009-05-29 2010-05-17 Flavonoid hydrogel
SG10201402723QA SG10201402723QA (en) 2009-05-29 2010-05-17 Flavonoid hydrogel

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201402723QA SG10201402723QA (en) 2009-05-29 2010-05-17 Flavonoid hydrogel

Country Status (5)

Country Link
US (3) US8541016B2 (enExample)
EP (1) EP2435504B1 (enExample)
JP (2) JP5843758B2 (enExample)
SG (2) SG176286A1 (enExample)
WO (1) WO2010138082A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909655B (zh) * 2007-10-23 2013-04-10 新加坡科技研究局 递送抗癌剂至细胞的方法
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
JP5954877B2 (ja) * 2010-03-11 2016-07-20 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 負荷率の改善が可能な抗癌剤送達ビヒクル
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) * 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
JP6552487B2 (ja) * 2013-06-18 2019-07-31 エージェンシー フォー サイエンス, テクノロジー アンド リサーチ 癌幹細胞を培養する方法
CN105658633A (zh) * 2013-09-03 2016-06-08 新加坡科技研究局 用于生物医药应用的聚合物-类黄酮缀合物和水凝胶
GB2518405A (en) * 2013-09-20 2015-03-25 Zeiss Carl Meditec Ag Composition comprising at least one viscoelastic polymer
WO2015070100A1 (en) 2013-11-08 2015-05-14 The Johns Hopkins University Oxygen-controllable and hypoxia-inducible hydrogels
US10004586B2 (en) 2014-08-27 2018-06-26 The Cleveland Clinic Foundation Biocompatible tissue graft
JP7162361B2 (ja) * 2018-04-02 2022-10-28 オプティファーム カンパニー リミテッド 細胞皮膜化用アルギン酸塩微細カプセル及びその製造方法
KR102326127B1 (ko) * 2019-06-27 2021-11-12 서울대학교산학협력단 녹차 유래 폴리페놀을 이용한 주입형 조직 접착 하이드로젤, 그의 제조 방법 및 그의 응용
WO2021113515A1 (en) * 2019-12-03 2021-06-10 The Schepens Eye Research Institute, Inc. Injectable hydrogels for cell delivery to the vitreous
CN113892643A (zh) * 2021-09-23 2022-01-07 西北农林科技大学 一种用于细胞培养肉的可食用的采用茶多酚涂层的海藻酸钠/明胶3d凝胶支架的制造方法
CN114736254B (zh) * 2022-03-30 2024-01-05 湖南大学 一种天然黄酮类化合物衍生物药物及其制备方法和应用
CN117046406B (zh) * 2023-08-15 2026-07-17 中国人民解放军军事科学院军事医学研究院 基于天然产物儿茶素的自组装水凝胶及制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US6982298B2 (en) * 2003-01-10 2006-01-03 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
AU2006248166B2 (en) 2005-05-20 2012-11-01 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
JP4712505B2 (ja) * 2005-09-30 2011-06-29 富士フイルム株式会社 電子内視鏡装置
US20090169532A1 (en) 2006-02-27 2009-07-02 Ying Jackie Y Curable bone cement
JP2007297360A (ja) * 2006-05-08 2007-11-15 Ihara Suisan Kk ハイドロゲル、その製造方法およびその用途
US20100008869A1 (en) 2006-07-21 2010-01-14 Kao Corporation Method for preventing coloration of catechins and dentifrice composition
JP4308230B2 (ja) * 2006-07-21 2009-08-05 花王株式会社 カテキン類の着色抑制方法
KR100968591B1 (ko) * 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
CN101909655B (zh) 2007-10-23 2013-04-10 新加坡科技研究局 递送抗癌剂至细胞的方法
US8287906B2 (en) 2008-05-06 2012-10-16 Agency For Science, Technology And Research Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
WO2009148405A1 (en) 2008-06-05 2009-12-10 Agency For Science, Technology And Research Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
JP5954877B2 (ja) 2010-03-11 2016-07-20 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 負荷率の改善が可能な抗癌剤送達ビヒクル

Also Published As

Publication number Publication date
EP2435504A4 (en) 2015-12-02
JP6112576B2 (ja) 2017-04-12
US9439886B2 (en) 2016-09-13
JP5843758B2 (ja) 2016-01-13
JP2016014025A (ja) 2016-01-28
WO2010138082A1 (en) 2010-12-02
EP2435504A1 (en) 2012-04-04
US20150313869A1 (en) 2015-11-05
US9034364B2 (en) 2015-05-19
EP2435504B1 (en) 2020-03-11
SG10201402723QA (en) 2014-10-30
US20130338101A1 (en) 2013-12-19
JP2012528150A (ja) 2012-11-12
US8541016B2 (en) 2013-09-24
US20120070433A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
US9439886B2 (en) Methods for producing crosslinked flavonoid hydrogels
Oh et al. Characterization of an oxidized alginate-gelatin hydrogel incorporating a COS-salicylic acid conjugate for wound healing
Ramya et al. Biomedical applications of chitosan: an overview
Liu et al. Thiol-mediated synthesis of hyaluronic acid–epigallocatechin-3-O-gallate conjugates for the formation of injectable hydrogels with free radical scavenging property and degradation resistance
EP2473210B1 (en) In situ-forming hydrogel for tissue adhesives and biomedical use thereof
EP1498128A1 (en) Medicinal compositions containing phtocrosslinkable chitosan derivative
US9226899B2 (en) Particulate hyaluronic acid and flavonoid formulations for cellular delivery of bioactive agents
Ryu et al. Dual mode gelation behavior of silk fibroin microgel embedded poly (ethylene glycol) hydrogels
Tsai et al. Injectable, shear-thinning, self-healing, and self-cross-linkable benzaldehyde-conjugated chitosan hydrogels as a tissue adhesive
JP6026039B1 (ja) 生医学的使用のためのビタミンで機能化したゲル形成ブロック・コポリマー
EP2560996B1 (en) Phase separated composite
JPWO2006121156A1 (ja) 皮膚再生を促進する医療用組成物
Zhao et al. Enzyme-crosslinked protocatechualdehyde acetal-modified polyvinyl alcohol hydrogel with acid-responsive and emerging photothermal properties for infected skin wound management
US12305209B2 (en) Cross-linking material having adhesive strength, prepared using Burkholderia-derived tyrosinase, preparation method therefor, and application thereof
Moriyama et al. Characterization of enzyme-crosslinked albumin hydrogel for cell encapsulation
Le Thi et al. Enhanced cytotoxicity of cisplatin-loaded Brij S100-alginate-taurine nanogels against HeLa cervical cancer cells
KR102709709B1 (ko) 주사 가능한 포도당 산화 효소 고정화 젤라틴 하이드로겔의 종양 재발 억제 용도
Belgodere Incorporation of lignin in natural and synthetic biomaterials to alter mechanical and biochemical properties for enhanced wound healing
Jeong et al. In Vitro Cellular Uptake and Transfection of Oligoarginine-Conjugated Glycol Chitosan/siRNA Nanoparticles. Polymers 2021, 13, 4219
Mora Boza Development of new bioactive systems for regenerative medicine using 3D printing and microfluidic technologies
Padmananabhan Evaluation of Biodegradability and Cell Functionality of Injectable Glycol Chitosan Hydrogel